The MarketWatch News Department was not involved in the creation of this content. Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to ...
U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension “This represents a paradigm ...
U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli â„¢ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 ...